Athersys, Inc. (ATHX)
Stock Price:
$1.85 USD
-0.05 (-2.63%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $1.84 -0.01 (-0.54%) Nov 30, 7:58 PM
Key Info
| Market Cap |
365.74M |
| Revenue (ttm) |
457,000 |
| Net Income (ttm) |
-66.48M |
| Shares Out |
197.70M |
| EPS (ttm) |
-0.38 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$1.85 |
| Previous Close |
$1.90 |
| Change ($) |
-0.05 |
| Change (%) |
-2.63% |
| Day's Open |
1.88 |
| Day's Range |
1.72 - 1.90 |
| Day's Volume |
3,294,687 |
| 52-Week Range |
1.16 - 3.98 |
More Stats
| Market Cap |
365.74M |
| Enterprise Value |
304.03M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
197.70M |
| Float |
n/a |
| EPS (basic) |
-0.37 |
| EPS (diluted) |
-0.38 |
| FCF / Share |
-0.28 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
27.20M |
| Short Ratio |
17.75 |
| Short % of Float |
n/a |
| Beta |
-1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
800.32 |
| PB Ratio |
7.92 |
| Revenue |
457,000 |
| Operating Income |
-66.40M |
| Net Income |
-66.48M |
| Free Cash Flow |
-55.57M |
| Net Cash |
61.71M |
| Net Cash / Share |
0.31 |
| Gross Margin |
-7,311.16% |
| Operating Margin |
-14,529.32% |
| Profit Margin |
-14,547.50% |
| FCF Margin |
-12,159.30% |
| ROA |
-71.37% |
| ROE |
-186.84% |
| ROIC |
703.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.25*
(237.84% upside)
Low
5.00
Current: $1.85
High
8.00
Target: 6.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 5.63 | 24.29 | 3.71 | 17.35 | 11.95 | 1.62 | 2.44 | 8.71 | 10.34 | 8.94 |
| Revenue Growth | -76.81% | 555.1% | -78.62% | 45.19% | 636.17% | -33.43% | -72% | -15.82% | 15.72% | - |
| Gross Profit | 5.63 | 24.29 | 3.71 | 17.35 | 11.95 | 1.62 | 2.44 | 8.71 | 10.34 | 8.94 |
| Operating Income | -45.49 | -25.05 | -33.28 | -15.03 | -17.17 | -29.01 | -24.46 | -16.00 | -13.78 | -11.51 |
| Net Income | -44.58 | -24.28 | -32.24 | -15.34 | -16.42 | -22.08 | -30.74 | -14.74 | -13.75 | -11.38 |
| Shares Outstanding | 152 | 137 | 112 | 84.72 | 82.14 | 76.95 | 57.67 | 32.56 | 23.24 | 18.93 |
| Earnings Per Share | -0.29 | -0.18 | -0.29 | -0.18 | -0.20 | -0.31 | -0.53 | -0.45 | -0.59 | -0.60 |
| Operating Cash Flow | -35.33 | -13.35 | -24.02 | -10.93 | -13.76 | -25.79 | -22.78 | -17.67 | -14.49 | -10.59 |
| Capital Expenditures | -0.58 | -1.53 | -0.29 | -1.71 | -0.13 | -0.30 | -0.39 | -0.35 | -0.59 | -0.39 |
| Free Cash Flow | -35.91 | -14.88 | -24.30 | -12.64 | -13.90 | -26.09 | -23.17 | -18.01 | -15.08 | -10.98 |
| Cash & Equivalents | 35.04 | 51.06 | 29.32 | 14.75 | 23.03 | 26.13 | 31.95 | 25.53 | 12.78 | 15.18 |
| Total Debt | - | - | - | - | 0.19 | 0.18 | 0.18 | 0.17 | - | - |
| Net Cash / Debt | 35.04 | 51.06 | 29.32 | 14.75 | 22.84 | 25.94 | 31.77 | 25.36 | 12.78 | 15.18 |
| Assets | 41.67 | 61.73 | 33.59 | 19.06 | 25.13 | 28.72 | 34.19 | 27.60 | 15.70 | 19.11 |
| Liabilities | 18.40 | 18.61 | 10.22 | 7.88 | 5.41 | 7.82 | 14.37 | 7.36 | 8.40 | 10.10 |
| Book Value | 23.27 | 43.12 | 23.38 | 11.18 | 19.72 | 20.90 | 19.82 | 20.25 | 7.30 | 9.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Athersys, Inc. |
| Country |
United States |
| Employees |
83 |
| CEO |
Gil van Bokkelen |
Stock Information
| Ticker Symbol |
ATHX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ATHX |
Description
Athersys, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.